Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avanos MedicalAVNS +0.04%62 Debt-to-EBITDA is 1.79 as of Mar. 2026. GuruFocus rates AVNS with a GF Score™ of 62/100 and a GF Value™ of $19.37 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Avanos Medical ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Avanos Medical's Debt-to-EBITDA or its related term are showing as below:
AVNS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -375 Med: -3.56 Max: 30.74
Current: -6.41
During the past 13 years, the highest Debt-to-EBITDA Ratio of Avanos Medical was 30.74. The lowest was -375.00. And the median was -3.56.
AVNS's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs AVNS: -6.41
Avanos Medical (NYSE:AVNS) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Avanos Medical Debt-to-EBITDA Related Terms
Avanos Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Avanos Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVNS vs LMRI, AORT, IRMD: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Avanos Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avanos Medical Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Avanos Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Avanos Medical (AVNS) has a Debt-to-EBITDA of 1.79 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Avanos Medical. According to the industry distribution chart, Avanos Medical ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Avanos Medical's Debt-to-EBITDA too high?
Avanos Medical's current Debt-to-EBITDA is 1.79. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Avanos Medical's value of 1.79 is 14% above this industry median. Based on the distribution chart, Avanos Medical ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avanos Medical has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avanos Medical's Debt-to-EBITDA compare to LMRI and AORT?
According to the Medical Devices & Instruments industry distribution chart, Avanos Medical ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Avanos Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Avanos Medical's value of 1.79 is 14% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avanos Medical's current Debt-to-EBITDA of 1.79 is 14% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Avanos Medical. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avanos Medical's current Debt-to-EBITDA is 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avanos Medical stock overvalued right now?
Based on GuruFocus' analysis, Avanos Medical (AVNS) is currently considered Modestly Overvalued. The stock's GF Value™ is $19.37, compared to a current price of $24.99 — trading 29% above its estimated fair value. The current Debt-to-EBITDA is 1.79 and 14% above the Medical Devices & Instruments industry median of 1.57. Avanos Medical's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Avanos Medical (AVNS), the current Debt-to-EBITDA is 1.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avanos Medical (AVNS) Overvalued in 2026?
Based on GuruFocus' analysis, Avanos Medical stock appears to be overvalued.
The current stock price of $24.99 is trading 29% above its estimated GF Value™ of $19.37.
GuruFocus considers Avanos Medical to be Modestly Overvalued.
Key valuation signals for AVNS:
Debt-to-EBITDA: 1.79
GF Value™: $19.37 vs. price of $24.99 (29% above fair value)
Industry Position: 14% above the Medical Devices & Instruments median (#999999 of 467)
No single metric tells the full story. See the AVNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
62GF Score
Get the complete analysis for AVNS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVNS has been successfully added to your 
